title: Effect of palonosetron on the QTc interval in patients undergoing sevoflurane anaesthesia.
abstract: BACKGROUND
  Palonosetron is a recently introduced 5-HT3 receptor antagonist for postoperative nausea and vomiting. Detailed standardized evaluation of corrected QT (QTc) interval change by palonosetron under sevoflurane anaesthesia is lacking. We evaluated QTc intervals in patients who are undergoing surgery with sevoflurane anaesthesia and receive palonosetron.
  
  
  METHODS
  Our study included 100 patients who were undergoing elective surgery under sevoflurane anaesthesia. The patients were randomly assigned to two groups: those who received an i.v. injection of palonosetron 0.075 mg immediately before induction of anaesthesia (pre-surgery group, n=50) and those who received it after surgery in the recovery room (post-surgery group, n=50). QTc intervals were measured before operation, intraoperatively (baseline, immediately after tracheal intubation, and at 2, 10, 15, 30, 60, and 90 min after administration of palonosetron or placebo), and after operation (before and at 3, and 10 min after administration of palonosetron or placebo). QTc intervals were calculated using Fridericia's, Bazett's, or Hodges formulas.
  
  
  RESULTS
  The perioperative QTc intervals were significantly increased from the baseline values, but were not affected by the pre- or post-surgical timing of palonosetron administration.
  
  
  CONCLUSIONS
  There was no significant difference in the QTc intervals during the perioperative period, whether 0.075 mg of palonosetron is administered before or after sevoflurane anaesthesia. Palonosetron may be safe in terms of QTc intervals during sevoflurane anaesthesia. Clinical trial registration ClinicalTrials.gov: NCT01650961.
authors.affiliation: Department of Anaesthesiology and Pain Medicine and.
authors.forename: H J
authors.initials: HJ
authors.lastname: Kim
authors.forename: H-C
authors.initials: HC
authors.lastname: Lee
authors.forename: Y S
authors.initials: YS
authors.lastname: Jung
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: J J
authors.initials: JJ
authors.lastname: Min
authors.forename: D-M
authors.initials: DM
authors.lastname: Hong
authors.forename: E-K
authors.initials: EK
authors.lastname: Choi
authors.forename: S
authors.initials: S
authors.lastname: Oh
authors.forename: Y
authors.initials: Y
authors.lastname: Jeon
mesh_terms: D000328:Adult; D000368:Aged; D000769:Anesthesia, Inhalation; D018685:Anesthetics, Inhalation; D000932:Antiemetics / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004562:Electrocardiography; D004573:Electrolytes / Q000097:blood; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects* / Q000627:therapeutic use; D008133:Long QT Syndrome / Q000139:chemically induced*; D008297:Male; D008738:Methyl Ethers; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D000077924:Palonosetron; D020250:Postoperative Nausea and Vomiting / Q000453:epidemiology / Q000517:prevention & control; D011812:Quinuclidines / Q000009:adverse effects* / Q000627:therapeutic use; D000077149:Sevoflurane; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018685:Anesthetics, Inhalation; D000932:Antiemetics; D004573:Electrolytes; D007546:Isoquinolines; D008738:Methyl Ethers; D011812:Quinuclidines; D000077149:Sevoflurane; D000077924:Palonosetron
keywords: anti-emetics; electrocardiography; palonosetron; postoperative nausea and vomiting; serotonin 5-HT3 receptor antagonists; sevoflurane